EZH2 Inhibition Enhances PD‐L1 Protein Stability Through USP22‐Mediated Deubiquitination in Colorectal Cancer
Jiaqi Huang,Qianqian Yin,Yuqing Wang,Xin Zhou,Yunyun Guo,Yuanjun Tang,Rui Cheng,Xiaotong Yu,Jie Zhang,Chen Huang,Zhanya Huang,Jianlin Zhang,Zhengyang Guo,Xiao Huo,Yan Sun,Yanfang Li,Hao Wang,Jianling Yang,Lixiang Xue
DOI: https://doi.org/10.1002/advs.202308045
IF: 15.1
2024-03-23
Advanced Science
Abstract:Inhibitors of EZH2 can activate the expression of deubiquitinase USP22 in colorectal cancer via canonical epigenetic regulation through H3K27me3, thereby stabilizing PD‐L1 protein and enhancing its expression, inducing immune evasion and diminishing the anti‐tumor therapeutic efficacy. Combination immunotherapy can block the immune suppression effects of EZH2 inhibitors and exert a combined anti‐cancer effect. The regulation of PD‐L1 is the key question, which largely determines the outcome of the immune checkpoint inhibitors (ICIs) based therapy. However, besides the transcription level, the protein stability of PD‐L1 is closely correlated with its function and has drawn increasing attention. In this study, EZH2 inhibition enhances PD‐L1 expression and protein stability, and the deubiquitinase ubiquitin‐specific peptidase 22 (USP22) is identified as a key mediator in this process. EZH2 inhibition transcriptionally upregulates USP22 expression, and upregulated USP22 further stabilizes PD‐L1. Importantly, a combination of EZH2 inhibitors with anti‐PD‐1 immune checkpoint blockade therapy improves the tumor microenvironment, enhances sensitivity to immunotherapy, and exerts synergistic anticancer effects. In addition, knocking down USP22 can potentially enhance the therapeutic efficacy of EZH2 inhibitors on colon cancer. These findings unveil the novel role of EZH2 inhibitors in tumor immune evasion by upregulating PD‐L1, and this drawback can be compensated by combining ICI immunotherapy. Therefore, these findings provide valuable insights into the EZH2‐USP22‐PD‐L1 regulatory axis, shedding light on the optimization of combining both immune checkpoint blockade and EZH2 inhibitor‐based epigenetic therapies to achieve more efficacies and accuracy in cancer treatment.
materials science, multidisciplinary,nanoscience & nanotechnology,chemistry